Everything below concerns pituitary axis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Periodic actin rings – A periodic structure constructed of evenly spaced actin rings is found in axons. In this structure, the actin rings, together with spectrin tetramers that link the neighboring actin rings, form a cohesive cytoskeleton that supports the axon membrane. The structure periodicity may also regulate the sodium ion channels in axons.
=== Repurposing for hair growth === When Upjohn received permission from the U.S. Food and Drug Administration (FDA) to test the new drug as medicine for hypertension they approached Charles A. Chidsey, at the University of Colorado School of Medicine. He conducted two studies, the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn (who while a dermatology resident at the University of Miami had been the first to observe and report hair development on patients using the minoxidil patch) and discussed the possibility of using minoxidil for treating hair loss. Kahn, along with his colleague Paul J. Grant, had obtained a certain amount of minoxidil and conducted their own research, since they were first to make the side effect observation. Neither Upjohn or Chidsey at the time were aware of the side effect of hair growth. The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids. Both parties filed patents to use minoxidil for hair loss prevention, which resulted in a decade-long trial between Kahn and Upjohn, which ended with Kahn's name included in a consolidated patent (U.S. #4,596,812 Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant. Meanwhile, the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients.
== Environmental impacts == Major threats that cold seep ecosystems and their communities face today are seafloor litter, chemical contaminants, and climate change. Seafloor litter alters the habitat by providing hard substrate where none was available before or by overlying the sediment, thereby inhibiting gas exchange and interfering with organisms on the bottom of the sea. Studies of marine litter in the Mediterranean include surveys of seabed debris on the continental shelf, slope, and bathyal plain. In most studies, plastic items accounted for much of the debris, sometimes as much as 90% or more of the total, owing to their ubiquitous use and poor degradability. Weapons and bombs have also been discarded at sea, and their dumping in open waters contributes to seafloor contamination. Another major threat to the benthic fauna is the presence of lost fishing gear, such as nets and longlines, which contribute to ghost fishing and can damage fragile ecosystems such as cold-water corals. Chemical contaminants such as persistent organic pollutants, toxic metals (e.g., Hg, Cd, Pb, Ni), radioactive compounds, pesticides, herbicides, and pharmaceuticals are also accumulating in deep-sea sediments. Topography (such as canyons) and hydrography (such as cascading events) play a major role in the transportation and accumulation of these chemicals from the coast and shelf to the deep basins, affecting the local fauna.
Sources: en.wikipedia.org
== Discovery == Since the 1960s, seryl-tRNA synthetases have been described in various eukaryotic species, in both biochemical and structural analyses. It was not until 1997 that human SARS and its enzyme product were isolated and expressed in Escherichia coli by a team from The European Molecular Biology Laboratory in France.
Dinoflagellates are the primary source of dinosteral. Dinoflagellates are unicellular, aquatic organisms that live in both marine and inland environments and are a prominent constituent of phytoplankton. Dinoflagellates are often characterized by their uncommon sterol distribution, dominated by 4α-methyl sterols derived from lanosterol rather than cycloartenol. In many cases, the most abundant sterol in dinoflagellates is dinosterol. Dinosterol is often used a biomarker in geochemical research because it is produced almost exclusively by dinoflagellates and is found in many environments. In addition to several species of dinoflagellates, dinosterol has also been isolated from the diatom Nivicula sp. (CS-46c) collected from Port Hacking, New South Wales, Australia.
Using the enediol intermediate of the reaction (which allowed solvent protons to enter the reaction from the middle instead of only from the substrate or product) and kinetic isotope effects, he measured the relative free energy of each intermediate and transition state, which allowed him to depict the first free energy profile for an enzyme-catalyzed reaction. This work was done with his long-term collaborator, John Albery. His profile showed that TIM was a "perfect" enzyme in that catalysis is limited only by the rate of diffusion. Later, Knowles applied similar methods to proline racemase, developing an elegant method to discern whether a reaction proceeds via a stepwise or concerted manner and discovering the consequences of "oversaturation", a situation in which the interconversion of unliganded forms of the enzyme limit catalysis. At Harvard, Knowles also did important work on β-lactamases and their mechanism-based inhibitors. And, he provided key insight on the stereochemistry of phosphoryl group transfer reactions, using synthetic phosphoryl groups containing 16O, 17O, and 18O isotopes. Knowles was the author of more than 250 research papers, and advised many doctoral students and post-doctoral researchers at Oxford and at Harvard, including Hagan Bayley, Stephen L. Buchwald, Athel Cornish-Bowden, Andreas Plückthun, and Ronald T. Raines.
Sources: en.wikipedia.org
=== Positive === Insulin secretion results in positive feedback in different ways. Firstly, insulin increases the uptake of glucose from blood by the translocation and exocytosis of GLUT4 storage vesicles in the muscle and fat cells. Secondly, it promotes the conversion of glucose into triglyceride in the liver, fat, and muscle cells. Finally, the cell will increase the rate of glycolysis within itself to break glucose in the cell into other components for tissue growth purposes. An example of positive feedback mechanism in the insulin transduction pathway is the activation of some enzymes that inhibit other enzymes from slowing or stopping the insulin transduction pathway which results in improved intake of the glucose. One of these pathways, involves the PI3K enzyme. This pathway is responsible for activating glycogen, lipid-protein synthesis, and specific gene expression of some proteins which will help in the intake of glucose. Different enzymes control this pathway. Some of these enzymes constrict the pathway causing a negative feedback like the GSK-3 pathway. Other enzymes will push the pathway forward causing a positive feedback like the AKT and P70 enzymes. When insulin binds to its receptor, it activates the glycogen synthesis by inhibiting the enzymes that slow down the PI3K pathway such as PKA enzyme. At the same time, it will promote the function of the enzymes that provide a positive feedback for the pathway like the AKT and P70 enzymes.
Dustin Andrew Fletcher (born 7 May 1975) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is widely acknowledged as one of the finest defenders in the history of the league, and one of only six players in the history of the VFL/AFL competition to play 400 games. Fletcher is a member of the Australian Football Hall of Fame, and a Legend in the Essendon Hall of Fame.
Micromeritics is the science of the behavior of particulate materials smaller than 75 μm. It is thus the study of the fundamental and derived properties of individual as well as a collection of particles. Micromeritics involves materials with larger particles than nanoparticles where they are smaller than 0.1 μm. The knowledge and control of the size of particles has importance in pharmacy and materials science. The size, and hence the surface area of a particle, can be related to the physical, chemical and pharmacological properties of drugs. Clinically, the particle size of a drug can affect its release from dosage forms that are administered orally, parenterally, rectally and topically. The successful formulation of suspensions, emulsions and tablets; both physical stability and pharmacological response also depends on the particle size achieved in the product.
=== Native chemical ligation === The most practical and robust method for the chemoselective reaction of unprotected peptides is native chemical ligation. The original chemical ligation methods involved the formation of a non-native bond at the ligation site. Subsequently, native chemical ligation was developed. In native chemical ligation, an unprotected peptide thioester reacts with the N-terminal cysteine of a second peptide to give a ligation product in which a native peptide bond joins the two peptide segments In this method, an initial thioester-linked ligation product intermediate rearranges to form an amide bond. Native chemical ligation overcomes the limitations of the classical synthetic organic chemistry approach to the total synthesis of proteins, and enabled the routine total or semi- synthesis of protein molecules. Native chemical ligation relies on the presence of a cysteine residue at the ligation site. Methods using removable auxiliary groups can in some instances extend the use of native chemical ligation to non-cysteine residues, as can the use of desulfurization subsequent to the ligation (e.g. converting a Cys to an Ala).
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.